Divergent Paths: Pharm Exec Profiles Five Recent Drug Launches

Author(s)Pharmaceutical Executive Editorial Staff

Pharm Exec’s latest sampling of notable biopharma brand approvals and launches all have unique stories to tell—from the winding journeys to innovative “firsts” to new momentum for milestones to come.

Follow the links below to read about each product:

Exxua (Fabre-Kramer Pharmaceuticals)

Omvoh (Eli Lilly)

Truqap (AstraZeneca)

Wegovy (Novo Nordisk)

Winrevair (Merck & Co.)

Articles in this issue

almost 2 years ago

Article

Pharmaceutical Executive: July/August 2024 Issue (PDF)

almost 2 years ago

Article

An AI Pulse Check

almost 2 years ago

Article

A Promising Option: Exxua

almost 2 years ago

Article

Opening the Door: Omvoh

almost 2 years ago

Article

'Marked’ for Stardom?: Truqap

almost 2 years ago

Article

Branching Off: Wegovy

almost 2 years ago

Article

A Formidable First: Winrevair

almost 2 years ago

Article

The Future of Launch Excellence is Generative AI

almost 2 years ago

Article

From Potential to Value: Carving a Slice of the CGT ‘PIE'

almost 2 years ago

Article

Big Bets, Bold Steps

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.